ANI Pharmaceuticals (ANIP) Guggenheim’s Inaugural Healthcare Innovation Conference summary

Business performance and segment highlights

• Achieved $148 million in sales for the quarter, with strong results across all business units.

• Rare Disease segment led growth, driven by Purified Cortrophin Gel and new ophthalmology assets from Alimera Sciences.

• Generics business posted high single-digit to low double-digit growth, supported by 16 new product launches and robust R&D.

• Established brands continued to generate strong cash flow, though expected to see modest decline without new deals.

• Rare Disease remains the primary focus for future capital allocation and business development.

Rare Disease franchise and Cortrophin Gel

• Cortrophin Gel sales grew from $42M in 2022 to $112M in 2023, with 2024 guidance of $196M–$200M (75–78% growth).

• Growth driven by expansion into new indications (pulmonology, ophthalmology) and increased commercial efforts.

• Significant multi-year growth opportunity exists due to underpenetrated patient pool and new gout indication.

• New product formats (1 mL vial, prefilled syringe) launched to improve patient convenience and access.

• Ongoing investment in scientific evidence and publications to support broader use.

Alimera Sciences acquisition and ophthalmology assets

• Acquired ILUVIEN and YUTIQ, both with long exclusivity and growth potential, synergistic with existing portfolio.

• Combined sales force expanded to 46 reps to promote all three Rare Disease products.

• ILUVIEN (for diabetic macular edema) and YUTIQ (for non-infectious uveitis) expected to deliver double-digit growth.

• NEW DAY trial for ILUVIEN could enable earlier use in DME, expanding patient pool; positive results would be upside.

• Durability of assets supported by challenging generic pathways and long clinical trial requirements.